Celgene Corporation (CELG): Today's Featured Health Care Winner - TheStreet

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Celgene Corporation



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.2%. By the end of trading, Celgene Corporation rose $1.55 (1.4%) to $114.55 on light volume. Throughout the day, 2,082,383 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3,145,700 shares. The stock ranged in a price between $113.10-$115.00 after having opened the day at $114.40 as compared to the previous trading day's close of $113.00. Other companies within the Health Care sector that increased today were:

CombiMatrix Corporation



), up 42.8%,

USMD Holdings



), up 17.5%,




), up 14.2% and

Oncolytics Biotech



), up 13.0%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $47.5 billion and is part of the drugs industry. The company has a P/E ratio of 34.6, above the S&P 500 P/E ratio of 17.7. Shares are up 44.0% year to date as of the close of trading on Monday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Celgene Corporation

as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Pingtan Marine Enterprise



), down 65.0%,

DARA Biosciences



), down 10.2%,

Infinity Pharmaceuticals



), down 9.9% and

China Pharma



), down 9.1% , were all laggards within the health care sector with

Boston Scientific



) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.